Search research articles
Contact Us
Filters
Showing results (1-10 of 108) with videos related to
Page
of 11
Sort By:
Oncoimmunology
|
June 22, 2012
The double-edge sword effect of anti-CD73 cancer therapy
John Stagg
Stem Cell Reviews
|
May 22, 2008
Mesenchymal stem cells in cancer
John Stagg
Therapeutic Advances in Medical Oncology
|
May 2, 2013
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
John Stagg, Bertrand Allard
Cancer Cell
|
August 17, 2010
Her 2 in 1
Mark J Smyth, John Stagg
Annual Review of Pharmacology and Toxicology
|
September 13, 2024
Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies
John Stagg, J Silvio Gutkind
Drug News & Perspectives
|
May 24, 2007
NK cell-based cancer immunotherapy
John Stagg, Mark J Smyth
Journal of Biomedicine & Biotechnology
|
November 6, 2012
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth
Bertrand Allard, Martin Turcotte, John Stagg
Methods in Molecular Biology (Clifton, N.J.)
|
September 2, 2016
Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies
Bertrand Allard, David Allard, John Stagg
Expert Opinion on Therapeutic Targets
|
May 7, 2014
Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
Bertrand Allard, Martin Turcotte, John Stagg
Breast Care (Basel, Switzerland)
|
August 2, 2013
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
John Stagg, Fabrice Andre, Sherene Loi
Page
of 11
Search research articles
Search
Showing results (1-10 of 108) with videos related to
Sort By:
Page
of 11
Oncoimmunology
|
June 22, 2012
The double-edge sword effect of anti-CD73 cancer therapy
John Stagg
Stem Cell Reviews
|
May 22, 2008
Mesenchymal stem cells in cancer
John Stagg
Therapeutic Advances in Medical Oncology
|
May 2, 2013
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
John Stagg, Bertrand Allard
Cancer Cell
|
August 17, 2010
Her 2 in 1
Mark J Smyth, John Stagg
Annual Review of Pharmacology and Toxicology
|
September 13, 2024
Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies
John Stagg, J Silvio Gutkind
Drug News & Perspectives
|
May 24, 2007
NK cell-based cancer immunotherapy
John Stagg, Mark J Smyth
Journal of Biomedicine & Biotechnology
|
November 6, 2012
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth
Bertrand Allard, Martin Turcotte, John Stagg
Methods in Molecular Biology (Clifton, N.J.)
|
September 2, 2016
Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies
Bertrand Allard, David Allard, John Stagg
Expert Opinion on Therapeutic Targets
|
May 7, 2014
Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
Bertrand Allard, Martin Turcotte, John Stagg
Breast Care (Basel, Switzerland)
|
August 2, 2013
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
John Stagg, Fabrice Andre, Sherene Loi
Page
of 11